AUTHOR=Wu Jiamin , Li Yi , Yu Jiayao , Gan Zhending , Wei Wenyao , Wang Chao , Zhang Lili , Wang Tian , Zhong Xiang 

TITLE=Resveratrol Attenuates High-Fat Diet Induced Hepatic Lipid Homeostasis Disorder and Decreases m6A RNA Methylation

JOURNAL=Frontiers in Pharmacology

VOLUME=11

YEAR=2020

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.568006

DOI=10.3389/fphar.2020.568006

ISSN=1663-9812

ABSTRACT=<p><bold>Purpose:</bold><italic>N</italic><sup>6</sup>-methyladenosine (m<sup>6</sup>A) mRNA methylation is affected by dietary factors and associated with lipid metabolism; however, whether the regulatory role of resveratrol in lipid metabolism is involved in m<sup>6</sup>A mRNA methylation remains unknown. Here, the objective of this study was to investigate the effect of resveratrol on hepatic lipid metabolism and m<sup>6</sup>A RNA methylation in the liver of mice.</p><p><bold>Methods:</bold> A total of 24 male mice were randomly allocated to LFD (low-fat diet), LFDR (low-fat diet + resveratrol), HFD (high-fat diet), and HFDR (high-fat diet + resveratrol) groups for 12 weeks (<italic>n</italic> = 6/group). Final body weight of mice was measured before sacrificing. Perirhemtric fat, abdominal and epididymal fat, liver tissues, and serum were collected at sacrifice and analyzed. Briefly, mice phenotype, lipid metabolic index, and m<sup>6</sup>A modification in the liver were assessed.</p><p><bold>Results:</bold> Compared to the HFD group, dietary resveratrol supplementation reduced the body weight and relative abdominal, epididymal, and perirhemtric fat weight in high-fat-exposed mice; however, resveratrol significantly increased average daily feed intake in mice given HFD. The amounts of serum low-density lipoprotein cholesterol (LDL), liver total cholesterol (TC), and triacylglycerol (TAG) were significantly decreased by resveratrol supplementation. In addition, resveratrol significantly enhanced the levels of peroxisome proliferator-activated receptor alpha (<italic>PPARα</italic>), peroxisome proliferator-activated receptor beta/delta (<italic>PPARβ/δ</italic>), cytochrome P450, family 4, subfamily a, polypeptide 10/14 (<italic>CYP4A10</italic>/<italic>14</italic>), acyl-CoA oxidase 1 (<italic>ACOX1</italic>), and fatty acid-binding protein 4 (<italic>FABP4</italic>) mRNA and inhibited acyl-CoA carboxylase (<italic>ACC</italic>) mRNA levels in the liver. Furthermore, the resveratrol in HFD increased the transcript levels of methyltransferase like 3 (<italic>METTL3</italic>), alkB homolog 5 (<italic>ALKBH5</italic>), fat mass and obesity associated protein (<italic>FTO</italic>), and YTH domain family 2 (<italic>YTHDF2</italic>), whereas it decreased the level of YTH domain family 3 (<italic>YTHDF3</italic>) and m<sup>6</sup>A abundance in mice liver.</p><p><bold>Conclusion:</bold> The beneficial effect of resveratrol on lipid metabolism disorder under HFD may be due to decrease of m<sup>6</sup>A RNA methylation and increase of <italic>PPARα</italic> mRNA, providing mechanistic insights into the function of resveratrol in alleviating the disturbance of lipid metabolism in mice.</p>